• Autoantibodies to GluA3 in the CSF of FTLD-tau patients and reduction of the GluA3 protein in the temporal cortex (Palese et al., 2020)• Increase in GluA2 subunit protein (Palese et al., 2020)• Reduction in intracortical facilitation in patients with GluA3 autoantibodies (Palese et al., 2020)• Increase in serine and glutamate in CSF of FTD-patients (Palese et al., 2020). This evidence concerns the gene MAPT and frontotemporal dementia.